Last reviewed · How we verify
Umkamin(Active Comparator)
Umkamin(Active Comparator) is a GLP-1 receptor agonist Small molecule drug developed by Hanlim Pharm. Co., Ltd.. It is currently in Phase 3 development for Type 2 diabetes. Also known as: Placebo of HL301 and Umkamin.
Umkamin is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Umkamin is a small molecule used as an active comparator in a clinical trial for acute bronchitis. It is being compared to HL301 in a multicenter, randomized, double-blinded, active-controlled, parallel, Phase III clinical trial.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Umkamin(Active Comparator) |
|---|---|
| Also known as | Placebo of HL301 and Umkamin |
| Sponsor | Hanlim Pharm. Co., Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
It works by mimicking the action of the natural hormone GLP-1, which increases insulin secretion and decreases glucagon levels, thereby lowering blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Umkamin(Active Comparator) CI brief — competitive landscape report
- Umkamin(Active Comparator) updates RSS · CI watch RSS
- Hanlim Pharm. Co., Ltd. portfolio CI
Frequently asked questions about Umkamin(Active Comparator)
What is Umkamin(Active Comparator)?
How does Umkamin(Active Comparator) work?
What is Umkamin(Active Comparator) used for?
Who makes Umkamin(Active Comparator)?
Is Umkamin(Active Comparator) also known as anything else?
What drug class is Umkamin(Active Comparator) in?
What development phase is Umkamin(Active Comparator) in?
What are the side effects of Umkamin(Active Comparator)?
What does Umkamin(Active Comparator) target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: Hanlim Pharm. Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Also known as: Placebo of HL301 and Umkamin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing